• Are Oral Dose Manufacturing Projects Becoming More Complicated?

    Has the complexity of oral dose manufacturing projects changed in recent years? Are CDMOs evaluated on the same metrics for simple and complex oral dose manufacturing projects? Data from ISR’s new report provides insight on these questions and more.

  • Choosing The Right CDMO For HPAPI Development, Manufacturing & Packaging

    Pharmaceutical companies recognize the importance of selecting the right partner for the development, manufacturing, packaging, and commercialization of products containing high-potency active pharmaceutical ingredients (HPAPIs). Experts discussed the key considerations and best practices when outsourcing HPAPI development, manufacturing and packaging to a CDMO.

  • Multidrug Combo For Companion Animals

    A leading multi-national animal healthcare client was working on a novel three-drug combination product for the treatment of seasonal ticks in companion animals. The client wanted to stabilize a low dose drug that is highly prone to hydrolytic degradation and also ensure content uniformity of the active within the microgram dosage.

  • The Shift Toward US Pharmaceutical Manufacturing

    The pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. Explore effective strategies to secure and de-risk pharmaceutical supply chains.

  • Orphan Drug Development – A Pragmatic Approach To Developing A Rare Disease Drug

    We are beginning to see a rise in the interest of developing "orphan drugs," or pharmaceutical agents intended to treat rare diseases. Discover challenges and considerations associated with the expedited development of orphan drugs and how to successfully work through them.

  • Commercial Manufacturing In Half The Time

    Due to US FDA requirements for commercial manufacturing of regulated (GMP) intermediates, a global pharma company quickly needed a dedicated production facility to produce its commercial antibiotic (carbapenem) intermediate.

  • We Are Asymchem

    We're a CDMO that researches the possibilities, develops new technologies, and applies new processes in a continual drive toward optimization.

  • Precision Powder-In-Capsule Micro-Dosing Accelerates Drug Product Development

    A key tool to address tight timelines and complex molecules is precision powder micro-dosing in capsules, which makes it possible to quickly get formulations to the clinic, saving time, money, and use of limited API, while avoiding premature termination of otherwise promising APIs.

  • Benefits Of RABS And Isolator Technology In A Changing Regulatory Landscape

    Restricted Access Barrier System (RABS) or isolator technologies represent an integral component of a manufacturer’s quality control strategy. The current regulatory landscape requires drug manufacturers to employ a RABS or isolator as part of their risk mitigation approach, and companies looking to develop in-house capabilities or contract to a CDMO should understand the key elements of each in order to make the best, most informed decision for their product.


  • Explore our full range of support services to streamline manufacturing processes through to commercialization of aseptic and lyophilized products.

  • An integrated supply chain, with transparency among sponsors and suppliers, ensures that regulatory starting materials (RSMs) are well characterized and free of impurities that can impact the final drug product.

  • Lonza’s global R&D center for mammalian cell processes is based in Slough, UK alongside a custom manufacturing facility. Lonza undertakes highly specialized development and manufacturing services for the pharmaceutical and biotechnology industries. Read more about Lonza’s complete range of R&D Services and an array of technologies and skills to best match their customers’ requirements for all stages of product development.

  • We offer a unique range of formulation and aseptic filling in vials, prefilled syringes, or cartridges to address production needs that span from small early stage clinical products to larger scale commercial products.

  • Bora Pharmaceuticals is a premier, international, cGMP CDMO specializing in complex oral solid dosages, liquids, semi-solids, pharmaceutical Rx and OTC products for clinical through commercial manufacturing, and serialization and packaging.